Dyslipidemia | Treatment Algorithms | Claims Data Analysis | US | 2017
Dyslipidemia is a key modifiable risk factor for cardiovascular (CV) disease. Current lipid-modifying therapies, including statins, ezetimibe, fibrates, omega-3 fatty acid compounds, and the novel proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, focus on improving lipid levels but ultimately aim to reduce the risk of CV events. Statins still dominate the market owing to their good risk-benefit profile and evidence for reducing CV morbidity and mortality. However, the evidence is not as strong for many of the non-statin therapies. Using a longitudinal claims data analysis we demonstrate how dyslipidemia is being treated in the United States, and provide insights into what is driving current prescribing practices for newly diagnosed and recently treated patients.
QUESTIONS ANSWERED
What patient share do key therapies and brands garner by line of therapy in newly diagnosed dyslipidemia patients?
What are the quarterly trends in prescribing among recently-treated and new diagnosed dyslipidemia patients?
How have Repatha and Praluent been integrated into the treatment algorithm?
What proportion of dyslipidemia patients receive drug therapy within one year of diagnosis, and how quickly?
What percentage of patients progress to later lines of therapy within one year of diagnosis?
What percentage of dyslipidemia patients are treated with monotherapy versus combination therapy?
What are the most widely used combination therapies?
What are the product-level compliance and persistency rates among drug-treated patients with dyslipidemia?
PRODUCT DESCRIPTION
Treatment Algorithms: Claims Data Analysis: Provides detailed analysis of brand usage across different lines of therapy using real-world data patient-level claims data so you can accurately assess your source of business and quantify areas of opportunity for increasing your brand share.